organization · Reporting owner
Sanderling Ventures VII, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CalciMedica, Inc.CALC · Entity 7804 | 10% owner | November 01, 2024 | November 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CalciMedica, Inc.
Report date November 01, 2024 · Filed November 05, 2024
Jointly reported with Sanderling Venture Partners VI Co Investment Fund LP, Sanderling Ventures Management VI, Sanderling VI Beteiligungs GmbH & Co KG, Sanderling Venture Partners VI LP, Sanderling VI Limited Partnership, Sanderling Ventures VII (Canada), L.P., Sanderling Ventures VII Annex Fund, L.P., Sanderling Ventures Management VII
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 814,300 |
Reported balance
After 2024-11-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-11-01 · Purchase · Acquired 86,867 · Balance 814,300 |
| Common StockSEC Table I · non-derivative | IndirectBy Sanderling Ventures Management VI | 22,479 |
Reported balance
After 2024-11-01 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-11-01 · Purchase · Acquired 877 · Balance 22,479 |
| Common StockSEC Table I · non-derivative | IndirectBy Sanderling Venture Partners VI, LP | 946,744 |
Reported balance
Holding disclosure · report date 2024-11-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 946,744 |
| Common StockSEC Table I · non-derivative | IndirectBy Sanderling VI Beteligungs GmbH & Co KG | 7,456 |
Reported balance
Holding disclosure · report date 2024-11-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 7,456 |
| Common StockSEC Table I · non-derivative | IndirectBy Sanderling VI Limited Partnership | 8,884 |
Reported balance
Holding disclosure · report date 2024-11-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 8,884 |
| Common StockSEC Table I · non-derivative | IndirectBy Sanderling Ventures VII, L.P. | 435,148 |
Reported balance
Holding disclosure · report date 2024-11-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 435,148 |
| Common StockSEC Table I · non-derivative | IndirectBy Sanderling Ventures VII (Canada), L.P. | 114,260 |
Reported balance
Holding disclosure · report date 2024-11-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 114,260 |
| Common StockSEC Table I · non-derivative | IndirectBy Sanderling Ventures VII Annex Fund, L.P. | 27,609 |
Reported balance
Holding disclosure · report date 2024-11-01 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 27,609 |
| Common StockSEC Table I · non-derivative | IndirectBy Sanderling Ventures Management VII | 30,292 |
Reported balance
Holding disclosure · report date 2024-11-01 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 30,292 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2024 Filed Nov 5, 2024 15:08 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 877 | $3.75 | $3,288.75 |
DisclosureSEC source: 0001415889-24-026103 · form4-11052024_081117.xml · nonDerivative · entry 2 Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VI Disclosed balance after: 22,479 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 15:08 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 86,867 | $3.75 | $325,751.25 |
DisclosureSEC source: 0001415889-24-026103 · form4-11052024_081117.xml · nonDerivative · entry 1 Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 814,300 Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseWarrant · Derivative | 14,372 | $0.13 Strike: $7.15 | $1,796.50 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 21 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VII Disclosed balance after: 14,372 Underlying: Common Stock · 14,372 shares Expires 2026-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseWarrant · Derivative | 14,372 | $0.13 Strike: $5.36 | $1,796.50 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 20 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VII Disclosed balance after: 14,372 Underlying: Common Stock · 14,372 shares Expires 2024-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseWarrant · Derivative | 1,960 | $0.13 Strike: $7.15 | $245.00 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 19 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VI Disclosed balance after: 1,960 Underlying: Common Stock · 1,960 shares Expires 2026-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseWarrant · Derivative | 1,960 | $0.13 Strike: $5.36 | $245.00 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 18 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VI Disclosed balance after: 1,960 Underlying: Common Stock · 1,960 shares Expires 2024-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseWarrant · Derivative | 6,592 | $0.13 Strike: $7.15 | $824.00 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 17 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P. Disclosed balance after: 6,592 Underlying: Common Stock · 6,592 shares Expires 2026-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseWarrant · Derivative | 6,592 | $0.13 Strike: $5.36 | $824.00 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 16 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P. Disclosed balance after: 6,592 Underlying: Common Stock · 6,592 shares Expires 2024-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseWarrant · Derivative | 25,516 | $0.13 Strike: $7.15 | $3,189.50 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 15 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII (Canada), L.P. Disclosed balance after: 25,516 Underlying: Common Stock · 25,516 shares Expires 2026-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseWarrant · Derivative | 25,516 | $0.13 Strike: $5.36 | $3,189.50 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 14 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII (Canada), L.P. Disclosed balance after: 25,516 Underlying: Common Stock · 25,516 shares Expires 2024-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseWarrant · Derivative | 97,236 | $0.13 Strike: $7.15 | $12,154.50 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 13 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII, L.P. Disclosed balance after: 97,236 Underlying: Common Stock · 97,236 shares Expires 2026-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseWarrant · Derivative | 97,236 | $0.13 Strike: $5.36 | $12,154.50 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 12 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII, L.P. Disclosed balance after: 97,236 Underlying: Common Stock · 97,236 shares Expires 2024-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseWarrant · Derivative | 72,338 | $0.13 Strike: $7.15 | $9,042.25 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 11 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P. Disclosed balance after: 72,338 Underlying: Common Stock · 72,338 shares Expires 2026-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseWarrant · Derivative | 72,338 | $0.13 Strike: $5.36 | $9,042.25 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 10 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P. Disclosed balance after: 72,338 Underlying: Common Stock · 72,338 shares Expires 2024-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseWarrant · Derivative | 121,678 | $0.13 Strike: $7.15 | $15,209.75 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 9 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,678 Underlying: Common Stock · 121,678 shares Expires 2026-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseWarrant · Derivative | 121,678 | $0.13 Strike: $5.36 | $15,209.75 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · derivative · entry 8 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,678 Underlying: Common Stock · 121,678 shares Expires 2024-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 28,744 | $3.70 | $106,410.29 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · nonDerivative · entry 7 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VII Disclosed balance after: 30,292 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 3,920 | $3.70 | $14,511.84 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · nonDerivative · entry 6 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VI Disclosed balance after: 21,602 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 13,184 | $3.70 | $48,807.17 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · nonDerivative · entry 5 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P. Disclosed balance after: 27,609 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 51,032 | $3.70 | $188,920.46 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · nonDerivative · entry 4 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII (Canada), L.P. Disclosed balance after: 114,260 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 194,472 | $3.70 | $719,935.34 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · nonDerivative · entry 3 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII, L.P. Disclosed balance after: 435,148 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 144,676 | $3.70 | $535,590.55 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · nonDerivative · entry 2 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P. Disclosed balance after: 727,433 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 243,356 | $3.70 | $900,903.91 |
DisclosureSEC source: 0001415889-24-001830 · form4-01252024_080106.xml · nonDerivative · entry 1 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 946,744 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 167 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 25 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VII Disclosed balance after: 167 Underlying: Common Stock · 167 shares Expires 2026-06-25 F27 · price: Received in exchange for a warrant to purchase 5,775 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 113 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 24 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VII Disclosed balance after: 113 Underlying: Common Stock · 113 shares Expires 2026-03-04 F26 · price: Received in exchange for a warrant to purchase 3,915 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 840 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 23 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P. Disclosed balance after: 840 Underlying: Common Stock · 840 shares Expires 2026-06-25 F25 · price: Received in exchange for a warrant to purchase 29,139 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 569 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 22 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P. Disclosed balance after: 569 Underlying: Common Stock · 569 shares Expires 2026-03-04 F24 · price: Received in exchange for a warrant to purchase 19,754 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 3,249 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 21 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII (Canada), LP Disclosed balance after: 3,249 Underlying: Common Stock · 3,249 shares Expires 2026-06-25 F23 · price: Received in exchange for a warrant to purchase 112,796 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 2,203 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 20 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII (Canada), LP Disclosed balance after: 2,203 Underlying: Common Stock · 2,203 shares Expires 2026-03-04 F22 · price: Received in exchange for a warrant to purchase 76,470 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 12,380 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 19 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII, LP Disclosed balance after: 12,380 Underlying: Common Stock · 12,380 shares Expires 2026-06-25 F21 · price: Received in exchange for a warrant to purchase 429,837 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 8,393 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 18 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII, LP Disclosed balance after: 8,393 Underlying: Common Stock · 8,393 shares Expires 2026-02-22 F20 · price: Received in exchange for a warrant to purchase 291,407 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 183 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 17 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VI Disclosed balance after: 183 Underlying: Common Stock · 183 shares Expires 2026-06-25 F19 · price: Received in exchange for a warrant to purchase 6,343 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 237 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 16 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VI Disclosed balance after: 237 Underlying: Common Stock · 237 shares Expires 2026-03-04 F18 · price: Received in exchange for a warrant to purchase 8,203 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 15,403 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 15 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P. Disclosed balance after: 15,403 Underlying: Common Stock · 15,403 shares Expires 2026-06-25 F17 · price: Received in exchange for a warrant to purchase 534,815 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 6,852 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 14 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P. Disclosed balance after: 6,852 Underlying: Common Stock · 6,852 shares Expires 2026-02-22 F16 · price: Received in exchange for a warrant to purchase 237,911 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 1,910 | Not disclosed Strike: $26.74 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 13 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P. Disclosed balance after: 1,910 Underlying: Common Stock · 1,910 shares Expires 2027-02-28 F15 · price: Received in exchange for a warrant to purchase 66,305 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 2,685 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 12 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,685 Underlying: Common Stock · 2,685 shares Expires 2026-06-25 F14 · price: Received in exchange for a warrant to purchase 93,225 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 16,539 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 11 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,539 Underlying: Common Stock · 16,539 shares Expires 2026-02-22 F13 · price: Received in exchange for a warrant to purchase 574,269 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 2,672 | Not disclosed Strike: $26.74 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 10 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,672 Underlying: Common Stock · 2,672 shares Expires 2027-02-28 F12 · price: Received in exchange for a warrant to purchase 92,748 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 1,548 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 9 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VII Disclosed balance after: 1,548 F10 · price: Received in exchange for 53,733 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 63,228 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 8 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII (Canada), L.P. Disclosed balance after: 63,228 F8 · price: Received in exchange for 2,195,354 shares of the common stock of CalciMedica pursuant to the Merger Agreement. F9 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 14,425 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 7 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P. Disclosed balance after: 14,425 F7 · price: Received in exchange for 500,854 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 240,676 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 6 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII, L.P. Disclosed balance after: 240,676 F6 · price: Received in exchange for 8,356,779 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 8,884 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 5 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling VI Limited Partnership Disclosed balance after: 8,884 F5 · price: Received in exchange for 308,455 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 7,456 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 4 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling VI Beteligungs GmbH & Co KG Disclosed balance after: 7,456 F4 · price: Received in exchange for 258,883 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 17,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 3 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VI Disclosed balance after: 17,682 F3 · price: Received in exchange for 613,943 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 582,757 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 2 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P. Disclosed balance after: 582,757 F2 · price: Received in exchange for 20,234,606 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 703,388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 1 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 703,388 F1 · price: Received in exchange for 24,423,158 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.